Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APLSNASDAQ:ARWRNASDAQ:COGTNASDAQ:MIRM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPLSApellis Pharmaceuticals$16.89-3.2%$19.33$16.10▼$43.76$2.12B0.732.27 million shs1.95 million shsARWRArrowhead Pharmaceuticals$15.37+1.6%$13.32$9.57▼$30.41$2.12B0.891.50 million shs1.28 million shsCOGTCogent Biosciences$4.88+1.2%$5.08$3.72▼$12.61$555.62M1.911.26 million shs1.58 million shsMIRMMirum Pharmaceuticals$43.87-0.3%$42.80$23.83▼$54.23$2.17B0.95522,522 shs293,688 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPLSApellis Pharmaceuticals-3.15%-8.75%-3.43%-35.90%-58.41%ARWRArrowhead Pharmaceuticals+1.59%-5.65%+16.00%-20.07%-38.22%COGTCogent Biosciences+1.24%-8.10%+5.17%-27.27%-40.63%MIRMMirum Pharmaceuticals-0.30%-3.24%+7.52%-13.16%+78.70%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPLSApellis Pharmaceuticals4.1852 of 5 stars4.30.00.04.42.82.50.6ARWRArrowhead Pharmaceuticals3.529 of 5 stars3.31.00.03.43.52.50.0COGTCogent Biosciences2.1369 of 5 stars4.40.00.00.03.30.00.6MIRMMirum Pharmaceuticals4.057 of 5 stars3.61.00.04.23.42.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPLSApellis Pharmaceuticals 2.62Moderate Buy$39.89136.20% UpsideARWRArrowhead Pharmaceuticals 2.67Moderate Buy$42.13174.07% UpsideCOGTCogent Biosciences 2.75Moderate Buy$14.00186.89% UpsideMIRMMirum Pharmaceuticals 3.17Buy$60.7338.43% UpsideCurrent Analyst Ratings BreakdownLatest COGT, APLS, MIRM, and ARWR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/22/2025APLSApellis PharmaceuticalsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$49.00 ➝ $41.005/20/2025ARWRArrowhead PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$80.00 ➝ $80.005/20/2025COGTCogent BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$14.00 ➝ $12.005/19/2025MIRMMirum PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy$73.005/14/2025APLSApellis PharmaceuticalsMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$30.00 ➝ $20.005/13/2025MIRMMirum PharmaceuticalsRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingStrong-Buy ➝ Strong-Buy5/13/2025ARWRArrowhead PharmaceuticalsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$21.00 ➝ $17.005/13/2025ARWRArrowhead PharmaceuticalsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$60.00 ➝ $60.005/13/2025MIRMMirum PharmaceuticalsRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetStrong-Buy ➝ Strong-Buy$73.00 ➝ $77.005/9/2025APLSApellis PharmaceuticalsRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Outperform$75.00 ➝ $52.005/9/2025APLSApellis PharmaceuticalsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral$41.00 ➝ $23.00(Data available from 5/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPLSApellis Pharmaceuticals$775.84M2.74N/AN/A$1.64 per share10.30ARWRArrowhead Pharmaceuticals$545.21M3.89N/AN/A$1.54 per share9.98COGTCogent BiosciencesN/AN/AN/AN/A$2.30 per shareN/AMIRMMirum Pharmaceuticals$379.25M5.73N/AN/A$5.33 per share8.23Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPLSApellis Pharmaceuticals-$528.63M-$1.79N/AN/AN/A-34.97%-103.11%-28.96%8/7/2025 (Estimated)ARWRArrowhead Pharmaceuticals-$599.49M-$1.40N/AN/AN/AN/A-236.60%-64.09%8/14/2025 (Estimated)COGTCogent Biosciences-$192.41M-$1.84N/AN/AN/AN/A-112.55%-60.44%8/5/2025 (Estimated)MIRMMirum Pharmaceuticals-$163.41M-$1.61N/AN/AN/A-31.69%-41.22%-14.81%8/6/2025 (Estimated)Latest COGT, APLS, MIRM, and ARWR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025MIRMMirum Pharmaceuticals-$0.35-$0.30+$0.05-$0.30$98.47 million$111.59 million5/12/2025Q2 2025ARWRArrowhead Pharmaceuticals-$0.06$2.75+$2.81$2.75$116.27 million$542.71 million5/7/2025Q1 2025APLSApellis Pharmaceuticals-$0.36-$0.74-$0.38-$0.74$197.61 million$149.90 million5/6/2025Q1 2025COGTCogent Biosciences-$0.56-$0.52+$0.04-$0.52N/AN/A2/28/2025Q4 2024APLSApellis Pharmaceuticals-$0.37-$0.29+$0.08-$0.29$197.92 million$212.50 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPLSApellis PharmaceuticalsN/AN/AN/AN/AN/AARWRArrowhead PharmaceuticalsN/AN/AN/AN/AN/ACOGTCogent BiosciencesN/AN/AN/AN/AN/AMIRMMirum PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPLSApellis Pharmaceuticals1.914.363.73ARWRArrowhead Pharmaceuticals7.276.096.09COGTCogent BiosciencesN/A6.446.44MIRMMirum Pharmaceuticals1.333.343.15Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPLSApellis Pharmaceuticals96.29%ARWRArrowhead Pharmaceuticals62.61%COGTCogent BiosciencesN/AMIRMMirum PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipAPLSApellis Pharmaceuticals6.50%ARWRArrowhead Pharmaceuticals4.30%COGTCogent Biosciences5.92%MIRMMirum Pharmaceuticals14.36%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPLSApellis Pharmaceuticals770125.68 million115.93 millionOptionableARWRArrowhead Pharmaceuticals400138.10 million120.68 millionOptionableCOGTCogent Biosciences80113.86 million103.92 millionOptionableMIRMMirum Pharmaceuticals14049.54 million37.03 millionOptionableCOGT, APLS, MIRM, and ARWR HeadlinesRecent News About These CompaniesMirum Pharmaceuticals’ SWOT analysis: rare disease stock shows growth potentialMay 27 at 8:41 PM | investing.comVoloridge Investment Management LLC Sells 85,242 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)May 27 at 4:39 AM | marketbeat.comTwo Sigma Advisers LP Trims Stock Holdings in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)May 26 at 4:26 AM | marketbeat.comWoodline Partners LP Acquires 73,399 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)May 24, 2025 | marketbeat.comNuveen Asset Management LLC Has $29.86 Million Stock Position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)May 24, 2025 | marketbeat.comEquities Analysts Offer Predictions for MIRM Q2 EarningsMay 23, 2025 | marketbeat.comMirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Shares Sold by Rafferty Asset Management LLCMay 23, 2025 | marketbeat.comMirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Shares Bought by Millennium Management LLCMay 23, 2025 | marketbeat.comMirum Pharmaceuticals at RBC Conference: Strategic Growth HighlightsMay 22, 2025 | uk.investing.comWhat is HC Wainwright's Estimate for MIRM Q2 Earnings?May 22, 2025 | americanbankingnews.comHC Wainwright Reaffirms Buy Rating for Mirum Pharmaceuticals (NASDAQ:MIRM)May 21, 2025 | marketbeat.comMirum Pharmaceuticals (NASDAQ:MIRM) Given Buy Rating at HC WainwrightMay 21, 2025 | americanbankingnews.comMirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Shares Sold by Tang Capital Management LLCMay 20, 2025 | marketbeat.comTema Etfs LLC Takes Position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)May 20, 2025 | marketbeat.comDeutsche Bank AG Has $7 Million Stake in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)May 20, 2025 | marketbeat.comMirum Pharmaceuticals Appoints Doug Sheehy, JD, as Chief Legal OfficerMay 19, 2025 | businesswire.comMirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Receives $60.64 Consensus Target Price from AnalystsMay 19, 2025 | americanbankingnews.comD. E. Shaw & Co. Inc. Purchases Shares of 157,352 Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)May 18, 2025 | marketbeat.comMirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Shares Sold by Prosight Management LPMay 17, 2025 | marketbeat.comBalyasny Asset Management L.P. Purchases New Holdings in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)May 17, 2025 | marketbeat.comNorthern Trust Corp Acquires 32,059 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)May 17, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCOGT, APLS, MIRM, and ARWR Company DescriptionsApellis Pharmaceuticals NASDAQ:APLS$16.89 -0.55 (-3.15%) Closing price 05/27/2025 04:00 PM EasternExtended Trading$16.84 -0.05 (-0.27%) As of 05/27/2025 07:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.Arrowhead Pharmaceuticals NASDAQ:ARWR$15.37 +0.24 (+1.59%) Closing price 05/27/2025 04:00 PM EasternExtended Trading$15.42 +0.05 (+0.33%) As of 05/27/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.Cogent Biosciences NASDAQ:COGT$4.88 +0.06 (+1.24%) Closing price 05/27/2025 04:00 PM EasternExtended Trading$4.93 +0.05 (+1.02%) As of 05/27/2025 05:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.Mirum Pharmaceuticals NASDAQ:MIRM$43.87 -0.13 (-0.30%) Closing price 05/27/2025 04:00 PM EasternExtended Trading$43.88 +0.01 (+0.01%) As of 05/27/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft's Outlook Brightens as Analysts Boost Bullish Ratings Palantir Scores First $1 Billion Contract; Is It Priced In? Tesla: Why Analysts Think It Could Jump Another 47% Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings Navitas Soars on NVIDIA Deal: Breaking Down Its Tech and Outlook 3 Dividend Stocks to Get You Through Tariff Volatility Apple Sinks After New 25% Tariff Announcement—What's The Bottom? MarketBeat Week in Review – 05/19 - 05/23 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
